JPRN-UMIN000010849已完成未知
Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapy - Study of add-on therapy with DPP-4 inhibitor in diabetic patients uncontrolled with BOT
Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2013年5月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with a history of hypersensitivity to vildagliptin 2)Patients with diabetic ketoacidosis, diabetic coma and type 1 diabetes 3)Patients with severe liver dysfunction 4)Patients with severe infection, perioperative and severe trauma 5)Patients with moderate renal dysfunction or endstage renal disease on hemodialysis 6)Patients with heart failure (NYHA/New York Heart Association stage 3 or severer) 7)Pituitary insufficiency or adrenal insufficiency 8)Patienst with diarrhea, vomiting, starvation and irregular food intake 9)Patients with proliferative diabetic retinopathy 10)Patients who are pregnant, lactating, and possibly pregnant women and those planning to become pregnant
研究者
相似试验
尚未招募
3 期
Effectiveness of Unani add-on therapy in preventing the disease severity of COVID-19 infectioCTRI/2020/12/029575Central Council for Research in Unani Medicine
招募中
2 期
Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathyTaxane-induced neuropathy.IRCT20090613002027N21Mazandaran University of Medical Sciences60
招募中
不适用
Assessment of the efficacy and safety of accessory nerve reconstruction using nerve regeneration inducing tube in neck dissection for patients with head and neck cancer - A Prospective Multicenter Clinical StudyHead and neck cancerJPRN-UMIN000032336Yokohama City University12
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.EUCTR2011-001493-25-ATovo Nordisk A/S420
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001493-25-DEovo Nordisk A/S420